CoChat

Population-Based Active Surveillance for Culture-Confirmed Candidemia — 10 Sites, United States, 2017–2021

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 34 of the 41 sources its claims cite were checked for support.

Abstract

Problem/Condition: Candidemia, a bloodstream infection caused by Candida spp., is a common cause of health care-associated bloodstream infections in the United States. Candidemia is associated with substantial health care costs, morbidity, and mortality. Period Covered: 2017-2021. Description of System: CDC's Emerging Infections Program (EIP), a collaboration among CDC, state health departments, and academic partners, was used to conduct active, population-based laboratory surveillance for candidemia at city or county sites located in 10 states (California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee), representing a combined population of approximately 21.5 million persons, or 7% of the U.S. population in 2019. Connecticut began reporting cases on January 1, 2019, and conducts statewide surveillance. Although candidemia is not a nationally notifiable condition, cases of Candida auris infection are nationally notifiable, and cases of candidemia caused by C. auris could be included in both national case counts and EIP surveillance. A culture-confirmed candidemia case is defined as a positive blood culture for any Candida sp. from a resident in the surveillance catchment area. Subsequent positive blood cultures for Candida within 30 days of the initial positive culture (index date) in the same patient are considered part of the same case. Clinical laboratories serving each catchment area report candidemia cases, and trained surveillance officers abstract information from medical charts for all cases. Corresponding isolates are sent to CDC for species confirmation and antifungal susceptibility testing. Results: A total of 7,381 candidemia cases were identified during the surveillance period (2017-2021). The overall incidence was 7.4 cases per 100,000 population. Across age groups, sexes, racial and ethnic groups, and surveillance sites, incidence was generally stable or increased slightly from 2017 to 2021, with the lowest overall incidence in 2019 (6.8) and the highest in 2021 (7.9). In 2021, candidemia incidence was highest in patients aged ≥65 years (22.7) and infants (aged <1 year) (8.0). Incidence was higher in males (8.7) compared with females (7.0) and higher in non-Hispanic Black or African American (Black) patients (12.8) compared with non-Black patients (5.6). Incidence was highest in Maryland (14.5), followed by Tennessee (10.1) and Georgia (10.0); incidence was lowest in Oregon (4.8). Increases occurred in the percentage of cases classified as health care onset (52.2% in 2017 to 58.0% in 2021). Overall, among 7,381 cases (in 6,235 patients), 63.7% occurred in patients who had a central venous catheter, 80.7% involved recent systemic antibiotic receipt, and 9.0% occurred in patients who had a history of injection drug use. The percentage of cases with a positive SARS-CoV-2 test during the 90 days before or after the index date increased from 10.4% in 2020 to 17.7% in 2021. From 2017 to 2021, the percentage of cases involving an intensive care unit stay before the index date increased from 38.3% to 44.9%. Echinocandins (e.g., micafungin) were used as treatment in 49.8% of cases, and azoles were used in 47.7%. The all-cause in-hospital mortality rate was 32.6%; this increased from 26.8% in 2019 to 36.1% in 2021. Overall, Candida albicans accounted for 37.1% of cases, followed by Candida glabrata (30.4%) and Candida parapsilosis (13.5%); however, C. glabrata was the most frequent species in California (38.4%) and Maryland (32.9%). Candida auris infections accounted for 0.4% of cases. Among 6,576 Candida isolates for which interpretive breakpoints exist and isolates were available for testing, 5.6% were fluconazole resistant, and <1% were echinocandin resistant. Antifungal resistance was stable for all antifungals tested across years. Interpretation: Candidemia remains an important health care-associated infection. The disproportionate incidence among older adults, males, and Black patients is consistent with previous reports, and the overall incidence of candidemia has not changed substantially compared with previous EIP findings based on data collected during 2012-2016 (8.7 per 100,000 population). The higher mortality rate associated with candidemia during 2020-2021 likely reflects consequences of the COVID-19 pandemic, including strained health care systems and an increased population of patients who were susceptible to candidemia because of COVID-19-related critical illness. Public Health Action: Strict implementation of measures to prevent health care-associated bloodstream infections is important to help prevent candidemia cases. Health care officials and providers should be vigilant for candidemia as a complication of critical illness. Continued surveillance is needed to monitor for emerging populations at risk for candidemia and changes in antifungal resistance patterns, which can help guide antifungal treatment selection.

Overview

CoChat Summary

TL;DR

CDC’s Emerging Infections Program conducted active, population-based surveillance for culture-confirmed candidemia at 10 U.S. sites during 2017–2021, identifying 7,381 cases from 6,235 patients. Overall incidence was 7.4 per 100,000 population, with stable-to-slightly-increased incidence over time and higher mortality in 2020–2021.

Key findings

  • Among 7,381 cases, overall candidemia incidence was 7.4 per 100,000 population; incidence was lowest in 2019 (6.8) and highest in 2021 (7.9). In 2021, incidence was highest among adults aged ≥65 years (22.7) and infants aged <1 year (8.0), higher in males (8.7) than females (7.0), and higher in Black patients (12.8) than non-Black patients (5.6).
  • Site incidence varied widely: Maryland had the highest incidence (14.5), followed by Tennessee (10.1) and Georgia (10.0), while Oregon had the lowest (4.8). Health care onset cases increased from 52.2% in 2017 to 58.0% in 2021; ICU stay before index date increased from 38.3% to 44.9%.
  • Common risk factors included central venous catheter (63.7%), recent systemic antibiotics (80.7%), and injection drug use (9.0%). Positive SARS-CoV-2 test during the 90 days before or after index date increased from 10.4% in 2020 to 17.7% in 2021.
  • Candida albicans accounted for 37.1% of cases, followed by C. glabrata (30.4%) and C. parapsilosis (13.5%); C. auris accounted for 0.4%. Among 6,576 isolates tested, 5.6% were fluconazole resistant and <1% were echinocandin resistant. All-cause in-hospital mortality was 32.6% overall and 36.1% in 2021.

Methods

  • Active, population-based laboratory surveillance through CDC’s Emerging Infections Program at 10 sites in California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee, representing approximately 21.5 million persons (about 7% of the U.S. population in 2019); Connecticut began reporting in 2019.
  • A case was a positive blood culture for any Candida sp. from a surveillance-area resident; positive cultures within 30 days of the initial culture were considered the same case. Clinical, reference, and commercial laboratories reported cases, and trained surveillance officers abstracted standardized case report forms from medical records.
  • Isolates were sent to CDC for species confirmation by MALDI-TOF or DNA sequencing and antifungal susceptibility testing by CLSI microdilution; analyses were descriptive, with annual incidence rates calculated using U.S. Census Bureau population estimates. Cases missing index date (<1%) were excluded.

Limitations

  • The paper states five limitations: data came from only 10 geographic areas, limiting representativeness; changes in data collection over years limited availability and interpretation of certain data; chart abstraction by surveillance personnel may have led to inconsistencies; some data elements are not systematically documented in charts, likely underestimating risk factors; and blood culture sensitivity is low, so some cases may have been missed.
  • Evident from the text: Connecticut began surveillance in 2019 and some variables were collected only in certain years, so 2017–2021 trends are not uniformly based on all sites or all years.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.15585/mmwr.ss7404a1

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Annual candidemia incidence,* overall and by age group — 10 sites,† United States, 2017–2021 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years (https://data.census.gov). † California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Connecticut is the only statewide surveillance site and started reporting in 2019.
FIGURE 1 Annual candidemia incidence,* overall and by age group — 10 sites,† United States, 2017–2021 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years (https://data.census.gov). † California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Connecticut is the only statewide surveillance site and started reporting in 2019.CC0 · PubMed Central
FIGURE 2 Annual candidemia incidence,* by sex — 10 sites,† United States, 2017–2021 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years (https://data.census.gov). † California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Connecticut is the only statewide surveillance site and started reporting in 2019.
FIGURE 2 Annual candidemia incidence,* by sex — 10 sites,† United States, 2017–2021 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years (https://data.census.gov). † California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Connecticut is the only statewide surveillance site and started reporting in 2019.CC0 · PubMed Central
FIGURE 3 Annual candidemia incidence,* by race and ethnicity — 10 sites,† United States, 2017–2021 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years (https://data.census.gov). † California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Connecticut is the only statewide surveillance site and started reporting in 2019.
FIGURE 3 Annual candidemia incidence,* by race and ethnicity — 10 sites,† United States, 2017–2021 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years (https://data.census.gov). † California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Connecticut is the only statewide surveillance site and started reporting in 2019.CC0 · PubMed Central
FIGURE 4 Annual candidemia incidence,* by site — 10 sites,† United States, 2017–2021 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years (https://data.census.gov). † Connecticut is the only statewide surveillance site and started reporting in 2019.
FIGURE 4 Annual candidemia incidence,* by site — 10 sites,† United States, 2017–2021 * Per 100,000 population, calculated from the U.S. Census Bureau population and housing unit estimates for the corresponding years (https://data.census.gov). † Connecticut is the only statewide surveillance site and started reporting in 2019.CC0 · PubMed Central
FIGURE 5 Candida species* distribution, by year — 10 sites,† United States, 2017–2021 * The category “Candida, other species” includes C. bracarensis, C. cacao, C. catenulata, C. dubliniensis, C. duobushaemulonii, C. famata, C. fermentati, C. glaebosa, C. guilliermondii, C. guilliermondii var. membrane, C. intermedia, C. kefyr, C. krusei, C. lipolytica, C. lusitaniae, C. magnoliae, C. metapsilosis, C. nivariensis, C. orthopsilosis, C. pararugosa, C. pelliculosa, C. quercitrusa, C. rugosa, C. spherica, C. sojae, C. sorbosa, C. sorbosivorans, C. utilis, Candida germ tube negative, and unknown. † California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Connecticut is the only statewide surveillance site and started reporting in 2019.
FIGURE 5 Candida species* distribution, by year — 10 sites,† United States, 2017–2021 * The category “Candida, other species” includes C. bracarensis, C. cacao, C. catenulata, C. dubliniensis, C. duobushaemulonii, C. famata, C. fermentati, C. glaebosa, C. guilliermondii, C. guilliermondii var. membrane, C. intermedia, C. kefyr, C. krusei, C. lipolytica, C. lusitaniae, C. magnoliae, C. metapsilosis, C. nivariensis, C. orthopsilosis, C. pararugosa, C. pelliculosa, C. quercitrusa, C. rugosa, C. spherica, C. sojae, C. sorbosa, C. sorbosivorans, C. utilis, Candida germ tube negative, and unknown. † California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Connecticut is the only statewide surveillance site and started reporting in 2019.CC0 · PubMed Central

Verification

Claims the paper makes

26 Valid · 0 Not valid · 3 Not checked · 95 Own results and interpretations

67 more claims · 4 with their cited sources checked

Create a free account to see all 124 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 41
  • Probably not a substantial claim. 23
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 24 references

Cited by

See all 43

Metadata

Authors
Jenkins, E. N., Gold, J. A. W., Benedict, K., Lockhart, S. R., Berkow, E. L., Dixon, T., Shack, S. L., Witt, L. S., Harrison, L. H., Seopaul, S., Correa, M. A., Fitzsimons, M., Jabarkhyl, Y., Barter, D., Czaja, C. A., Johnston, H., Markus, T., Schaffner, W., Gross, A., Lynfield, R., Tourdot, L., Nadle, J., Roland, J., Escutia, G., Zhang, A. Y., Gellert, A., Hurley, C., Tesini, B. L., Phipps, E. C., Davis, S. S., & Lyman, M.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • Colorado Department of Public Health and Environment (US)
  • Emory University (US)
  • Johns Hopkins University (US)
  • Yale University (US)
  • Vanderbilt University Medical Center (US)
  • Minnesota Department of Health (US)
  • Oregon Health Authority (US)
  • University of Rochester Medicine (US)
Corresponding author
Jenkins, Emily N.
Venue
MMWR. Surveillance Summaries
Published
2025-05-29
Volume
74
Issue
4
Pages
1-15
ISSN
  • 1545-8636 (ISSN-L)
  • 1546-0738
OpenAlex
W4410775086
Cited by
43
References
24
Citations by year
2026: 35 · 2025: 8
FWCI
32.80
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • MMWR Surveillance Summaries (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
  • Minnesota Department of Health
  • Yale University
  • Vanderbilt University
  • Colorado Department of Public Health and Environment
  • Vanderbilt University Medical Center
  • Georgia Department of Public Health
  • Centers for Disease Control and Prevention
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords
candidemia, Candida, bloodstream infection, nosocomial infections, incidence trends, Candida auris, antifungal susceptibility, emerging infectious diseases, Emerging Infections Program, population-based surveillance, age and sex differences, racial and ethnic disparities, regional variation, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, Tennessee, United States
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Candida, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Population Surveillance, United States, Young Adult, Candidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Population-Based Active Surveillance for Culture-Confirmed Candidemia — 10 Sites, United States, 2017–2021. https://app.cochat.ai/papers/10.15585/mmwr.ss7404a1
The paper
Jenkins, E. N., Gold, J. A. W., Benedict, K., Lockhart, S. R., Berkow, E. L., Dixon, T., Shack, S. L., Witt, L. S., Harrison, L. H., Seopaul, S., Correa, M. A., Fitzsimons, M., Jabarkhyl, Y., Barter, D., Czaja, C. A., Johnston, H., Markus, T., Schaffner, W., Gross, A., . . . Lyman, M. (2025). Population-Based Active Surveillance for Culture-Confirmed Candidemia — 10 Sites, United States, 2017–2021. MMWR. Surveillance Summaries. https://doi.org/10.15585/mmwr.ss7404a1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.